Pembrolizumab (anti-PD-1)

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1[1][2].

Product Specifications

CAS Number

[9007-83-4]

Product Name Alternative

MK-3475 (anti-PD-1) ; Lambrolizumab (anti-PD-1)

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pembrolizumab-anti-pd-1.html

Purity

99.90

Solubility

H2O

Smiles

[Pembrolizumab(anti-PD-1)]

Molecular Weight

(146.341 kDa)

References & Citations

[1]Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) . Lancet. 2017 Aug 16. pii: S0140-6736 (17) 31601-X.|[2]England CG, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58 (1) :162-168.